iBio (NYSE American:IBIO) and CC-Pharming of Beijing are holding a four-day design and strategic planning meeting at iBio’s development and manufacturing facility in Bryan, Texas.
The meeting initiates the first stage of the companies’ business collaboration and will include work on product, process, and facility design for a monoclonal therapeutic antibody product: a plant-derived, bio-better rituximab.
The FDA approved rituximab in 1997 for the treatment of certain B-cell non-Hodgkin lymphomas.
CC-Pharming and iBio also expect to jointly select additional products for development and joint exclusive sales in China using iBio’s proprietary plant-based approach.
“We have a shared vision to bring significant product benefits of iBio’s technology and capabilities, combined with those of CC-Pharming, to the people of China and to expand our work with CC-Pharming to achieve solid commercial success for both companies,” Robert Kay, chairman and CEO of iBio, said in a statement.
Ms. Yujiao Chen, CC-Pharming’s VP for international business and intellectual property, said iBio’s superior technology will help CC-Pharming rapidly expand its product pipeline to meet the demand of the market in China.
